Physician profile
Ashley R Carson
NPI 1235417510
$2,512.54
in general payments reported to CMS, 2019-2025
13 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $481 · 2020: $285 · 2021: $406 · 2022: $467 · 2023: $316 · 2024: $411 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $872.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $927.72 | 2019-2023 | Total30 |
| Biotissue Holdings INC. | $371.03 | 2022-2024 | |
| Johnson & Johnson Vision Care, INC. | $313.83 | 2019-2025 | Acuvue |
| Coopervision INC. | $240.13 | 2022-2023 | Cvi Contact Lens |
| Bausch & Lomb Americas INC. | $206.72 | 2022-2025 | Infuse |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $122.97 | 2019 | |
| Alcon Research LLC | $104.71 | 2019 | |
| Ivantis, INC | $67.79 | 2021 | |
| Abbvie INC. | $58.62 | 2023 | Xen Glaucoma Treatment System, Alphagan P, Lumigan |
| Sun Pharmaceutical Industries INC. | $48.28 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $23.24 | 2025 | Xdemvy |
| Shire North American Group INC | $16.89 | 2019 | |
| Glaxosmithkline, LLC. | $10.61 | 2023 | Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Carson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.